Evaluation of Combination Treatment Efficacy of PI3K Inhibitors in PC-3 and MCF7 Cell Viability Assays

Class I Phosphoinositide 3-kinase (PI3K) proteins have been extensively characterized with respect to their roles in cell proliferation and tumorigenesis, and therefore serve as desirable targets for oncogenic drug development. Class I PI3K isoform-specific inhibitors provide elucidation of the individual isoform functionality, and the dependence particular cell types have on it. In this application note, the impact of PI3K isoform-selective inhibitors on the viability of PC3 and MCF-7 prostate cancer cells is evaluated.